Autologous attack on amyloidosis

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 874-876

  Gertz, Morie A ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; AUTOANTIGEN; CONGO RED; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; BONE MARROW BIOPSY; EDITORIAL; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MONOCLONAL IMMUNOGLOBULINEMIA; NERVE BIOPSY; RISK ASSESSMENT; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 33745593747     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.874     Document Type: Editorial

References (18)

1. Katzmann JA, Dispenzieri A, Abraham RS, Kyle RA. Performance of free light chain assays in clinical practice [abstract]. Blood. 2004; 104(11, pt 1): 216a. Abstract 757.
2. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma. 2005;6:208-219.
3. Gertz MA, Greipp PR, Kyle RA. Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med. 1991;118:33-39.
4. Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry. 2001;40:3525-3535.
5. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
6. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93:1062-1066.
7. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha Interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004 Dec 1; 104:3520-3526. Epub 2004 Aug 12.
8. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15;103:2936-2938. Epub 2003 Dec 18.
9. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther. 2006;6:343-360.
10. Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of fust-year survival after stem cell transplantation in AL amyloidosis patients. Blood. 2005 Nov 15;106:3353-3357. Epub 2005 Jul 21.
11. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34: 1025-1031.
12. Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a center for international blood and marrow transplant research study. Mayo Clin Proc. 2006;81:880-888.
13. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol. 2005;18:709-727.
14. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004;34:149-154.
15. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
16. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15;103:3960-3963. Epub 2004 Jan 22.
17. Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup) [abstract]. Blood. 2005;106(11, pt 1):127a. Abstract 421.
18. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid. 2005;12:120-126.